Leukemia Clinical Trials

Showing 4381-4400 of 10,987 trials

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

NCT01522469

This is a Phase II open label study of crenolanib besylate. This study will enroll subjects with relapsed or refractory AML with FLT3 activating mutations. Prior treatment with other FLT3 TKIs is allowed. Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.

Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations

Arog Pharmaceuticals, Inc.14 participantsStarted Jul 2012

Dallas, Texas, United States

RECRUITINGPhase 2

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

NCT05260528

The trial is a randomized, open-label phase II study comparing CPX-351 vs conventional intensivechemotherapy in patients with newly diagnosed de novo AML and intermediate- or adverse-risk genetics (according to 2017 ELN criteria)

Acute Myeloid Leukemia

Centre Hospitalier Universitaire de Nice210 participantsStarted May 2023

Amiens, France • Avignon, France • Besançon, France +27 more locations

Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations

CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

Related Searches

A Study of TY-1091 in Patients With Advanced Solid Tumors

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Feasibility of a New Diagnostic Device to Assess Small Intestinal Dysbiosis in Routine Clinical Setting.

An Observational Study on Predicting the Efficacy of Immunotherapy for NSCLC Based on LIRAscore

Stopping Cognitive Decline and Dementia by Fighting Covert Cerebral Small Vessel Disease

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLL

SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

A Multicenter Retrospective Review of Management Strategies in Small Bowel Obstruction

BIO 300 Non-Small Cell Lung Cancer Study

A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL

Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia

A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

The Impact of an Evidence-based Myth-busting Information Intervention on Maternal Food Allergy Related Quality of Life, Anxiety and Self-efficacy

Ipilimumab and Local Radiation for Selected Solid Tumors

Weight Variations Impacts on the Ankle of the Child

Effectiveness of Telerehabilitation in Balance Training Program

CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors